Strengthening Corporate Ethics, Legal Compliance and Internal Controls
First written in FY2016. 6 of 9 entries say "Advanced", first in FY2024. Latest entry: FY2026.
The whole theme swung hardest in 2022: 1 of 10 companies on the "Worse" side.
24 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「1. Compliance Committee (held 8 times) ・2 internal reports and 39 internal disciplinary actions 2. Recurrence Prevention Committee (held 14 times) ・Regarding bribery incidents and alleged bribery incidents involving the Company ・Establishment of a special committee composed of external attorneys independent of the Company ・Investigation by the special committee into the reported incidents and similar incidents (Investigation report published on 27 March 2026) ・Formulation of recurrence prevention measures (published on 27 March 2026)」
Specific activities to strengthen corporate ethics and legal compliance progressed, including meetings of the Compliance Committee and Recurrence Prevention Committee, internal reports and disciplinary actions, an investigation by a special committee of external attorneys, and publication of recurrence prevention measures. - FY2024AdvancedAnnual report
「Compliance Committee held 3 times; compliance training for new employees; training for officers (FY2023 management seminar/March); regulations instructor training held 2 times」
Specific compliance and corporate ethics activities were presented, including Compliance Committee meetings, training for officers and new employees, and regulations instructor training. - FY2020RestatedAnnual report
「The Company has also established a code of conduct for officers and employees, developed regulations for the Compliance Committee, and established an internal reporting system with internal and external consultation channels. It is enhancing corporate ethics and legal compliance and working to ensure thorough compliance with the Antimonopoly Act, the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices, and Other Products, and the Fair Competition Code for the Medical Devices Industry, an industry self-regulation.」
The system for corporate ethics and legal compliance through the code of conduct, Compliance Committee, internal reporting system and other measures has been reaffirmed. - FY2017RestatedAnnual report
「The Company has established a code of conduct for officers and employees, developed regulations for the Compliance Committee, and established an internal reporting system with internal and external consultation channels. It is enhancing corporate ethics and legal compliance and working to ensure thorough compliance with the Antimonopoly Act, the Pharmaceutical Affairs Act, and the Fair Competition Code for the Medical Devices Industry, an industry self-regulation.」
Systems for corporate ethics and legal compliance through the code of conduct, Compliance Committee, internal reporting system and other measures are reiterated. - FY2016First statedAnnual report
「The Company has established a code of conduct for officers and employees, developed regulations for the Compliance Committee, and established an internal reporting system with internal and external consultation channels. It is enhancing corporate ethics and legal compliance and working to ensure thorough compliance with the Antimonopoly Act, the Pharmaceutical Affairs Act, and the Fair Competition Code for the Medical Devices Industry, an industry self-regulation.」
The Company describes specific systems including a code of conduct, a Compliance Committee, an internal reporting system and internal audits.